Lilly announced it had struck a $375 million deal with the government for 300,000 vials of the antibody treatment, pending EUA, to be delivered in the two months after.

Drugmaker Eli Lilly said Tuesday it is pausing its trial of a combination antibody treatment for coronavirus for safety reasons. Usually, clinical trials are paused because a volunteer has ...

U.S. health officials warned that drugs from Regeneron and Eli Lilly should no longer be used because both have shown to be ineffective against the dominant omicron variant of the virus.

Another important coronavirus trial is underway from Eli Lilly for a new technology that could help treat or even prevent COVID-19. Another important trial is underway to combat COVID-19.

Eli Lilly and Co. (NYSE: LLY) has received a pair of firm-fixed-price contracts worth $2.73 billion combined from the U.S. Army Contracting Command to produce monoclonal antibody drugs for COVID-19.